Daily Coffee Consumption Linked to Lower Risk of Atrial Fibrillation, New Study Finds
Table of Contents
A daily cup of coffee may offer unexpected heart benefits, according to groundbreaking research published November 9 in JAMA. A new study challenges long-held medical advice and suggests that caffeinated coffee is not detrimental to heart health – and may even protect against atrial fibrillation (AFib), a common and possibly dangerous heart rhythm disorder.
For years, medical professionals cautioned individuals with AFib and other cardiac conditions to limit or avoid caffeine, fearing it could exacerbate symptoms.However, researchers from UC San Francisco and the University of Adelaide have discovered the opposite: participants who regularly consumed at least one cup of caffeinated coffee daily experienced a 39% reduction in their risk of developing AFib.
The Rising Tide of AFib and a Reversal of conventional Wisdom
Atrial fibrillation occurs when the heart beats too quickly and irregularly, increasing the risk of stroke and heart failure. The incidence of AFib is on the rise, driven largely by aging populations and increasing rates of obesity. Currently, more than 10 million adults in the United States have been diagnosed with the condition, and experts estimate that as many as one in three people may experience it during their lifetime.
This new research prompted a reevaluation of established guidelines. “Doctors have always recommended that patients with problematic AFib minimize their coffee intake, but this trial suggests that coffee is not only safe but likely to be protective,” explained a lead researcher from UCSF, the University of Adelaide, and the Royal Adelaide hospital.
How Coffee May Benefit Heart Health
The study, formally known as DECAF (Does Eliminating Coffee Avoid Fibrillation?), was the first randomized clinical trial designed to specifically investigate the relationship between caffeinated coffee and AFib. Researchers theorize several mechanisms could explain the protective effect.
“Coffee increases physical activity which is known to reduce atrial fibrillation,” stated a senior author of the study, an electrophysiologist at UCSF Health.He further elaborated that “caffeine is also a diuretic, which could potentially reduce blood pressure and in turn lessen AFib risk. Several other ingredients in coffee also have anti-inflammatory properties that could have positive effects.”
Researchers also propose that individuals who drink coffee may be substituting it for less healthy beverages, such as sugary sodas, contributing to overall improved health.
The DECAF Trial: Methodology and Results
The DECAF trial involved 200 patients who were regular coffee drinkers and had either persistent AFib or a related condition, atrial flutter, along with a documented history of AFib. All participants were scheduled to undergo electrical cardioversion, a procedure utilizing a controlled electrical shock to restore a normal heart rhythm.
Participants were randomly assigned to one of two groups: one group continued to consume at least one cup of caffeinated coffee or an espresso shot daily, while the other group completely abstained from coffee and other caffeinated beverages for six months. The results were striking. At the conclusion of the study, the group that continued to drink coffee experienced a 39% lower risk of recurring AFib episodes.
Implications and Future Research
The findings challenge decades of medical advice and open new avenues for understanding and managing afib. While further research is needed to fully elucidate the mechanisms at play, this study provides compelling evidence that moderate coffee consumption is unlikely to be harmful – and may even be beneficial – for individuals at risk of or living with AFib.
The research team included a broad collaboration of experts from UCSF, including Gabrielle Montenegro, Hannah H. Oo, Isabella J. Pena, Janet J. Tang, Grace Wall, Thomas A. Dewland, Joshua D. Moss, Edward P. Gerstenfeld, Zian H.Tseng, Henry H. Hsia, Randall J. Lee, Jeffrey E. Olgin,Vasanth Vedantham,Melvin M. Scheinman, and Catherine Lee. The project was funded by the national Institutes of Health.
